Evaluation of new formulations of antihelmintic drugs for the treatment of schistosomiasis
Abstract Squistosomiasis is a disease caused by trematode parasites of Schistosoma genus. It mainly affects tropical and subtropical areas, remains a major global health problem because of its high incidence in these regions. One of the most important species, because of its prevalence and severity, is Schistosoma mansoni, responsible for intestinal schistosomiasis. The treatment of choice is praziquantel, which exhibit high rates of clinical efficacy. However, this drug doesn’t prevent reinfection and therapeutic failure is frequently observed in endemic areas. Therefore, the search for therapeutic alternatives is urgently required. The objective of this assay was to evaluate in-vitro two types of praziquantel nanoparticles formulations (type A and type S) and, also, an alternative treatment with ivermectin against the adult stage of S. mansoni. The results showed that treatment with such nanoparticles has a similar or better efficiency than the available praziquantel powder. However, treatment with ivermectin didn’t provide evidence of greater effectiveness. Futures studies will be carried out to evaluate these formulations in different biological phases, as well as to perform in vivo studies using an experimental model.
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
AMSE.es [Internet]. España: Asociación de Médicos de Sanidad Exterior; 2011 [actualizado Abril 2013; acceso Junio 2016]. Disponible en: http://www.amse.es.
Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanism of action, resistance, and new derivatives of Schistosomiasis. Current Opinion in Infectious Diseases, (2008); 21: 659–667.
Gryseels B, Karja P, Clerinx J, Kestens L. Human schistosomiasis. Lancet, 2006: 368: 1106-18.
Hemen A, Kela SL, Istifanus WA. Chemotherapeutic Trials of Praziquantel and Ivermectin on victims of Urinary Schistosomiasis in Taraba North Senatorial District. Sci-Afric Journal of Scientific Issues, 2014; 2(4): 156-159.
Ismail M, Botros S, Metwally S, Farghally A, Tao LF, Day TA et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. The american Journal of Tropical Medicine and Hygiene, (1999); 60: 932-935.
Muro A, Pérez del Villar L, Velasco V, Pérez Arellano JL. Infecciones por trematodos. Medicine. 2010; 10(53): 3171-28.
Ribeiro de Souza AL, Andreani T, Nunes de Oliveira R, Princila Kiill C, Kolenyak dos Santos F, Marques Allegretti S et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. International Journal of Pharmaceutics, 2014; 463: 31-37.
Scalise ML, Arrúa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies. American Journal of Tropical Medicine and Hygiene, (2016). PMID: 27246447
Shoop WL, Ostlind DA, Rohrer SP, Mickle G, Haines HW, Michael BF et al. Avermectins and Milbemycins Against Fasciola hepatica: In Vivo Drug Efficacy and In Vitro Receptor Binding. International Journal for Parasitology, (1995); 25(8): 923-927.
Taman A, Samar EB, Nora ET, Amira EH, Manar A. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. Journal of Coastal Life Medicine, 2014; 2(10): 817-823.
Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang YS. Schistosomiasis. Current Protocols in Immunology, (2013); 19(1): 1-58. doi:10.1002/0471142735.im1901s103.
Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Transactions of the Royal Society of Tropical Medicine and Hygiene, (1991); 85(2): 232-4.
WHO.int [Internet]. Organización Mundial de la Salud [actualizado Enero 2016; citado Junio 2016]. Disponible en: http://www.who.int/mediacentre/factsheets/fs115/es/
Yepes E, Varela-M RE, López-Abán J, Rojas-Caraballo J, Muro A, Mollinedo F (2015). Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. PLoS Neglected Tropical Disease 9(7): e0003893. doi:10.1371/journal. pntd.0003893.
Yepes E, Varela-M RE, López-Abán J, Habib Dakir EL, Mollinedo F, Muro A. In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine. PLoS ONE, (2014): 9(10): e109431. doi:10.1371/journal.pone.0109431.
Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanism of action, resistance, and new derivatives of Schistosomiasis. Current Opinion in Infectious Diseases, (2008); 21: 659–667.
Gryseels B, Karja P, Clerinx J, Kestens L. Human schistosomiasis. Lancet, 2006: 368: 1106-18.
Hemen A, Kela SL, Istifanus WA. Chemotherapeutic Trials of Praziquantel and Ivermectin on victims of Urinary Schistosomiasis in Taraba North Senatorial District. Sci-Afric Journal of Scientific Issues, 2014; 2(4): 156-159.
Ismail M, Botros S, Metwally S, Farghally A, Tao LF, Day TA et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. The american Journal of Tropical Medicine and Hygiene, (1999); 60: 932-935.
Muro A, Pérez del Villar L, Velasco V, Pérez Arellano JL. Infecciones por trematodos. Medicine. 2010; 10(53): 3171-28.
Ribeiro de Souza AL, Andreani T, Nunes de Oliveira R, Princila Kiill C, Kolenyak dos Santos F, Marques Allegretti S et al. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. International Journal of Pharmaceutics, 2014; 463: 31-37.
Scalise ML, Arrúa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies. American Journal of Tropical Medicine and Hygiene, (2016). PMID: 27246447
Shoop WL, Ostlind DA, Rohrer SP, Mickle G, Haines HW, Michael BF et al. Avermectins and Milbemycins Against Fasciola hepatica: In Vivo Drug Efficacy and In Vitro Receptor Binding. International Journal for Parasitology, (1995); 25(8): 923-927.
Taman A, Samar EB, Nora ET, Amira EH, Manar A. Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. Journal of Coastal Life Medicine, 2014; 2(10): 817-823.
Tucker MS, Karunaratne LB, Lewis FA, Freitas TC, Liang YS. Schistosomiasis. Current Protocols in Immunology, (2013); 19(1): 1-58. doi:10.1002/0471142735.im1901s103.
Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Transactions of the Royal Society of Tropical Medicine and Hygiene, (1991); 85(2): 232-4.
WHO.int [Internet]. Organización Mundial de la Salud [actualizado Enero 2016; citado Junio 2016]. Disponible en: http://www.who.int/mediacentre/factsheets/fs115/es/
Yepes E, Varela-M RE, López-Abán J, Rojas-Caraballo J, Muro A, Mollinedo F (2015). Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. PLoS Neglected Tropical Disease 9(7): e0003893. doi:10.1371/journal. pntd.0003893.
Yepes E, Varela-M RE, López-Abán J, Habib Dakir EL, Mollinedo F, Muro A. In Vitro and In Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine. PLoS ONE, (2014): 9(10): e109431. doi:10.1371/journal.pone.0109431.
Castrillejo, S. A., López Abán, J., Salomon, C. J., Pastor Navarro, M., Pedraz, J. L., & Muro, A. (2017). Evaluation of new formulations of antihelmintic drugs for the treatment of schistosomiasis. FarmaJournal, 2(2), 27–37. Retrieved from https://revistas.usal.es/cinco/index.php/2445-1355/article/view/16010
Most read articles by the same author(s)
- Carlos Rivas, Carmen Vieira, Antonio Muro, Distribution of Tick Bites Removed from People during the COVID-19 Pandemic in Castilla y León , FarmaJournal: Vol. 8 No. 1 (2023)
- Luis Hernández, Carmen Viera, Antonio Muro, Detection of Rickettsia spp. in ticks fixed on people in Castilla y León , FarmaJournal: Vol. 5 No. 1 (2020)
- Cristina Martín, Pedro Fernandez-Soto, Antonio Muro, Assessment of the SmMIT-LAMP technique for the molecular detection of Schistosoma mansoni DNA in urine samples , FarmaJournal: Vol. 1 No. 1 (2016)
- Antonio Muro, Innovation in Pharmacy: Advances and Perspectives. IPAP18 , FarmaJournal: Vol. 3 No. 1 (2018)
- Jesús Morán, Darwin A Moreno-Pérez, Manuel A Patarroyo, Antonio Muro, Malaria proteomic research , FarmaJournal: Vol. 1 No. 1 (2016)
Downloads
Download data is not yet available.
+
−